Miracogen is focused on advancing antibody-drug conjugate (ADC) technology, which combines the targeting capabilities of antibodies with the potent cytotoxic effects of drugs. This innovative approach allows for the selective delivery of therapeutic agents directly to cancer cells, minimizing damage to healthy tissues and enhancing treatment efficacy. The company is developing a range of ADC products, including those targeting specific biomarkers such as Claudin 18.2 and EGFR, which are associated with various types of cancers. This targeted strategy aims to improve patient outcomes by providing more effective and less toxic treatment options.

In addition to ADC technology, Miracogen is actively engaged in research and development to expand its product pipeline. The company is committed to exploring novel therapeutic targets and enhancing the precision of cancer treatments. Their ongoing projects, such as MRG001, MRG002, MRG003, and MRG004, reflect a strategic focus on developing innovative solutions that address unmet medical needs in oncology. Through these efforts, Miracogen aims to position itself as a leader in the biopharmaceutical industry, dedicated to improving the lives of patients battling cancer.

China

Shanghai Miracogen is a biotechnology company that offers development, clinical research, and industrialization of new products for the treatment of various diseases such as breast cancer and non-small cell lung cancer. The company is a clinical stage biotech company fully owned by Lepu Biopharma.

Cancer

Miracogen

Non-small cell lung carcinoma

MRG003

Antibodies

Biologics

No. 1238 Zhangjiang Rd, Building 3, Suite 4E, Pudong District, Shanghai, 201203, China

Miracogen

Company Details